These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15142400)

  • 1. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports.
    Brown TE
    J Child Adolesc Psychopharmacol; 2004; 14(1):129-36. PubMed ID: 15142400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.
    Jaworowski S; Benarroch F; Gross-Tsur V
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):365-70. PubMed ID: 16768644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
    Ozbaran B; Kose S; Yuzuguldu O; Atar B; Aydin C
    World J Biol Psychiatry; 2015; 16(8):619-24. PubMed ID: 26223958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reading outcomes of children and adolescents with attention-deficit/hyperactivity disorder and dyslexia following atomoxetine treatment.
    Shaywitz BA; Williams DW; Fox BK; Wietecha LA
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):419-25. PubMed ID: 25299355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatments and approaches for attention deficit hyperactivity disorder.
    Newcorn JH
    Curr Psychiatry Rep; 2001 Apr; 3(2):87-91. PubMed ID: 11276402
    [No Abstract]   [Full Text] [Related]  

  • 8. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders.
    Hah M; Chang K
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):996-1004. PubMed ID: 16379520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine and nonresponders to stimulants.
    Velcea G; Winsberg BG
    Am J Psychiatry; 2004 Sep; 161(9):1718-9. PubMed ID: 15337674
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.
    Isaksson J; Hogmark Å; Nilsson KW; Lindblad F
    Psychiatry Res; 2013 Oct; 209(3):740-1. PubMed ID: 23850434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New options in the pharmacological management of attention-deficit/hyperactivity disorder.
    Olfson M
    Am J Manag Care; 2004 Jul; 10(4 Suppl):S117-24. PubMed ID: 15352538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract]   [Full Text] [Related]  

  • 16. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
    Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
    Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of attention deficit hyperactivity disorder in adults.
    Greenfield B; Hechman L
    Expert Rev Neurother; 2005 Jan; 5(1):107-21. PubMed ID: 15853481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical treatments of hyperactive child].
    Le Heuzey MF
    Arch Pediatr; 2004 Jan; 11(1):64-9. PubMed ID: 14700769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study.
    Charnsil C
    J Atten Disord; 2011 Nov; 15(8):684-9. PubMed ID: 20686100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.